Stockreport

Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma

Monopar Therapeutics Inc.  (MNPR) 
PDF WILMETTE, Ill., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprieta [Read more]